FDA DEVICE FACTS
EndoLIF Delta-Cage and DoubleWedge-Cage
Joimax GmbH
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The EndoLIF ® Delta-Cage and DoubleWedge-Cage are intended for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2-S1. Degenera tive disc disease is defined as discogenic back pain with degenerati on of the disc c onfirmed by patient history and radiographic studies. These patients may also have up to Grade I spondylolisthesis at the involved leve l(s). These patient s may have had previous non-fusion spinal surgery at the involved spinal level(s). EndoLIF® Delta-Cage and DoubleWedge-Cag e are to be used with autogeneous bone and implanted via a posterior or posteriolateral approach. The EndoLIF ® Delta-Cage and DoubleWedge-Cage are to be used with supplemental FDA cleared fixation. Patie nts should have at least six (6) months of non-operative treatment pr ior to treatment with an EndoLIF ® cage.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。